Intersurgical connector recall adds to a week of device detachment and manufacturing alerts

What happened

On 10 November, FDA published an early alert on Intersurgical's 22mm Smoothbore breathing tubes and systems. According to the alert, too little bonding solvent was used in manufacture. That may allow soft connectors to separate from the tubing, with a risk of loss of ventilation.

Intersurgical has told US customers to stop using the products and to quarantine 12 affected product codes. The records do not say how many units are involved, whether injuries or complaints have been reported, or whether customers outside the US are affected. Those points are not yet known from the source material and should be checked against the full FDA notice and any manufacturer communication.

The failure mode is simple but the consequence is serious. A breathing circuit that disconnects can interrupt ventilation. The alert ties the problem to a specific manufacturing parameter, the amount of bonding solvent, rather than to how clinicians use the device.

A pattern across the week's device alerts

The Intersurgical alert did not arrive alone. The same day, FDA issued an early alert on Arrow International, a Teleflex subsidiary. Arrow told customers to quarantine spring wire guides and PICC or JACC catheters whose hydrophilic coating may detach and release particles into the bloodstream.

Health Canada also listed a Type I recall of Merit Medical's Surfacer Inside-Out access catheter system, covering the Workstation Sheath and Dilator, over a detaching radiopaque tip. The listing cites four complaints, two involving adverse events. On 9 November FDA classed the Abiomed Automated Impella Controller removal as Class I. It cited quality issues that could delay therapy or cause loss of haemodynamic support.

These are different products and different failure modes. Even so, the first three involve a component or coating separating from the device. All four sit in the high-severity categories regulators reserve for risk of serious harm. The records do not link these events to one another, and nothing here suggests a common cause. The shared lesson is about detection: separation failures can be rare, intermittent and easy to misattribute at the bedside.

Why it matters for pharmacovigilance and device vigilance teams

The Merit entry is the only one in this set that quantifies the signal, and it is small: four complaints, two with adverse events. That is a reminder that a Type I classification does not need a large complaint volume. It depends on the potential seriousness of the harm.

For teams handling combination products, drug-device kits or ventilation and vascular-access consumables alongside medicines, the practical issue is complaint triage. A report describing a disconnection, a detached tip or particulate matter may be logged as a product quality complaint with no adverse event attached. If the event reaches a patient, it may also be a reportable safety event. Intake processes should capture both pathways and make sure the quality and safety functions see the same case.

The Intersurgical alert also shows the value of tracing a failure to a process input. A solvent quantity is a manufacturing control. If it is the root cause, the relevant evidence sits in batch records and supplier and process data, not only in clinical narratives. Safety teams that can pull lot numbers and product codes quickly will be better placed to scope exposure.

Regulatory context: lot-linked signals are not only a device issue

The same week's PRAC highlights, as reported by Slovenia's JAZMP, offer a medicines parallel. The EMA safety committee started a signal assessment of allergic reactions to human normal immunoglobulins, linked to specific batches. As with the device alerts, the question is whether a defined set of lots or product codes carries the risk, and that shapes the response.

Early alerts and recall classifications follow their own procedures. FDA's early alerts communicate potential high-risk device issues, and Class I and Type I are the most serious recall categories in the US and Canada respectively. A PRAC signal assessment is a structured review of whether a safety association is supported, and may lead to a recommendation. The Abiomed entry shows how an action can be reclassified upward as the assessment develops, so teams should expect the severity picture to change after first publication.

Elsewhere in the same set, PRAC opened a referral on flupentixol/melitracen (Deanxit) over serious neurological and psychiatric effects. FDA ordered a NAION warning on all GLP-1 receptor agonist labels. CBER is examining tumours with vector integration near the GLI1 oncogene in postmarketing reports for Zolgensma and Itvisma. These are class-wide or product-specific signal stories rather than manufacturing stories, but they share the same dependency on well-coded, well-documented case reports.

What to watch

For Intersurgical, watch for updates to the FDA alert: any reported injuries or deaths, the number of units affected, the final recall classification and whether other regions issue notices. For Arrow, the same questions apply to coating detachment and particle release.

Teams should also watch whether the Merit complaint count grows and whether other regulators publish matching actions. The Zolgensma review and the PRAC referral and signal assessments are separate tracks. Any decision from them would be new information that the records do not yet contain.